Clinical Trial Update: Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer

View source ↗

Summary

The clinical trial assessing PD-L1 imaging with 89Zr-atezolizumab in metastatic triple-negative breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: Karolinska University Hospital | Conditions: Metastatic Triple-Negative Breast Carcinoma | Status: TERMINATED